Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)

Creative Commons License

Turkkan G., Alkan A., PAYDAŞ S., TANRIVERDİ Ö., Karakas Y., Karadurmus N., ...More

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.36, no.4, pp.640-645, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.1007/s12288-020-01257-0
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE
  • Page Numbers: pp.640-645
  • Keywords: Marginal zone lymphoma, MALT lymphoma, Chemotherapy, Radiotherapy, Prognosis, B-CELL LYMPHOMA, IMPROVING SURVIVAL, PHASE-II, RITUXIMAB, THERAPY, EPIDEMIOLOGY, CONSORTIUM, PATTERNS
  • Hacettepe University Affiliated: Yes


Marginal zone lymphomas (MZLs) are rare and indolent subtypes of non-Hodgkin lymphomas, and their clinical behaviours are heterogeneous. The aim of this study was to evaluate the clinical and prognostic characteristics of MZL. In this multicentre retrospective study, we analyzed demographical, clinical and prognostic features of 64 MZL patients. The median age was 54.0 and 78.1% of the patients had extra-nodal disease at presentation. Most of the patients were treated with chemotherapy. The 5 years and 10 years overall survival (OS) rates were 74.5% and 62.1%, respectively. The analysis of factors associated with OS showed that ECOG performance score was an important prognostic factor, with 133.0 months (95% CI 49.3-216.5) versus 18.0 months (95% CI 12.1-23.7) for ECOG 0-1 and 2-3, respectively (p = 0.011). Prognosis of MZL is favorable and ECOG performance score was found associated with OS. Further detailed studies with large patient numbers are needed to clarify the clinical features and treatment management of MZLs.